{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:31:04Z","timestamp":1761766264573,"version":"3.37.3"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T00:00:00Z","timestamp":1520985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2018,5]]},"abstract":"Summary<\/jats:title>People with hepatitis C virus (HCV<\/jats:styled-content>) infection other than genotype 1 represent a heterogeneous group. The aim of the phase 2 C\u2010SCAPE<\/jats:styled-content> study was to evaluate elbasvir\/grazoprevir (EBR<\/jats:styled-content>\/GZR<\/jats:styled-content>), with or without ribavirin (RBV<\/jats:styled-content>), in participants with HCV<\/jats:styled-content> genotype 2, 4, 5 or 6 infection. This was a part randomised, open\u2010label, parallel\u2010group study (NCT<\/jats:styled-content>01932762; PN<\/jats:styled-content>047\u201003) of treatment\u2010naive, noncirrhotic participants. Participants with HCV<\/jats:styled-content> genotype 2 infection received GZR<\/jats:styled-content> 100\u00a0mg\u00a0+\u00a0RBV<\/jats:styled-content>\u00a0\u00b1\u00a0EBR<\/jats:styled-content> 50\u00a0mg for 12\u00a0weeks and those with genotype 4, 5 or 6 infection were randomized to receive EBR<\/jats:styled-content>\/GZR<\/jats:styled-content>\u00a0\u00b1\u00a0RBV<\/jats:styled-content> for 12\u00a0weeks. The primary endpoint was sustained virological response 12 weeks after completion of treatment (SVR12; HCV RNA<\/jats:styled-content> <25\u00a0IU\/mL). Among participants with genotype 2 infection, SVR<\/jats:styled-content>12 was achieved by 80% (24\/30) of those receiving EBR<\/jats:styled-content>\/GZR<\/jats:styled-content>\u00a0+\u00a0RBV<\/jats:styled-content> and 73% (19\/26) of those receiving GZR<\/jats:styled-content>\u00a0+\u00a0RBV<\/jats:styled-content>. SVR<\/jats:styled-content> rates were high in participants with HCV<\/jats:styled-content> genotype 4 infection receiving EBR<\/jats:styled-content>\/GZR<\/jats:styled-content> with and without RBV<\/jats:styled-content> (100% [10\/10] and 90% [9\/10]; respectively). In contrast, the addition of RBV<\/jats:styled-content> to EBR<\/jats:styled-content>\/GZR<\/jats:styled-content> appeared to increase SVR<\/jats:styled-content>12 in participants with genotype 5 infection (EBR<\/jats:styled-content>\/GZR<\/jats:styled-content>, 25%; EBR<\/jats:styled-content>\/GZR<\/jats:styled-content>\u00a0+\u00a0RBV<\/jats:styled-content> 100% [4\/4]). In participants with genotype 6 infection, SVR<\/jats:styled-content>12 was 75% (3\/4) in both those receiving EBR<\/jats:styled-content>\/GZR<\/jats:styled-content> and those receiving EBR<\/jats:styled-content>\/GZR<\/jats:styled-content>\u00a0+\u00a0RBV<\/jats:styled-content>. The safety profile was similar across treatment arms, with adverse events tending to occur more frequently among participants receiving RBV<\/jats:styled-content>. In conclusion, these data support the inclusion of participants with genotype 4 or 6 infection in the EBR<\/jats:styled-content>\/GZR<\/jats:styled-content> phase 3 studies. EBR<\/jats:styled-content>\/GZR<\/jats:styled-content>\u00a0\u00b1\u00a0RBV<\/jats:styled-content> was unsatisfactory for participants with genotype 2 or 5 infection.<\/jats:p>","DOI":"10.1111\/jvh.12801","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T05:12:39Z","timestamp":1511154759000},"page":"457-464","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety of 12\u00a0weeks of elbasvir\u00a0\u00b1\u00a0grazoprevir\u00a0\u00b1 ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C\u2010SCAPE study"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3167-7087","authenticated-orcid":false,"given":"A.","family":"Brown","sequence":"first","affiliation":[{"name":"Imperial College Healthcare NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"H\u00e9zode","sequence":"additional","affiliation":[{"name":"Henri Mondor Hospital University of Paris\u2010Est Creteil France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"Liver Unit Carmel Medical Center Technion Faculty of Medicine Haifa Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. R.","family":"Foster","sequence":"additional","affiliation":[{"name":"Liver Unit Queen Mary University of London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zekry","sequence":"additional","affiliation":[{"name":"St George Hospital Clinical School Inflammation and Infection Research Centre University of New South Wales Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-7997","authenticated-orcid":false,"given":"S. K.","family":"Roberts","sequence":"additional","affiliation":[{"name":"The Alfred Hospital Melbourne VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lahser","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Durkan","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Badshah","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Robertson","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wahl","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Barr","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Haber","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the C\u2010SCAPE Study Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_9_4_1","unstructured":"GaneEJ HylandRH AnD et\u00a0al.High efficacy of LDV\/SOF regimens for 12\u00a0weeks for patients with HCV genotype 3 or 6 infection: ELECTRON\u20101. Presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7\u201011 2014; Boston MA."},{"issue":"1","key":"e_1_2_9_5_1","first-page":"321A","article-title":"All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial","volume":"60","author":"Kapoor R","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30070-2"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"issue":"1","key":"e_1_2_9_10_1","first-page":"220A","article-title":"Evaluation of sofosbuvir and simeprevir\u2010based regimens in the TRIO network: academic and community treatment of a real\u2010world, heterogeneous population","volume":"60","author":"Dieterich D","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30151-3"},{"key":"e_1_2_9_13_1","unstructured":"Merck & Co. Inc.Zepatier (elbasvir and grazoprevir) tablets for oral use. Prescribing Information.https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf. Accessed November 13 2017."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00114-9"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.09.045"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.009"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00324-12"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201300343"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00363-17"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.12801","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T20:47:41Z","timestamp":1694810861000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,14]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/jvh.12801"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12801","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"type":"print","value":"1352-0504"},{"type":"electronic","value":"1365-2893"}],"subject":[],"published":{"date-parts":[[2018,3,14]]}}}